CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 61 enrolled
Drug / intervention
Enoxaparindrug
Likely dose
Enoxaparin 1mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06795698
NCT06795698Phase 2Completed
CompareCT.gov

The Effect of Prophylactic Anticoagulation on Major Bleeding Events in Hospitalized Chronic Kidney Disease and Lower Limb Fracture Patients. a Phase 2, Randomized, Doble Blind, Control Trial

Hospital Civil de Guadalajara·interventional·Posted Jan 28, 2025·Updated Jan 28, 2025

In Brief

A Phase 2 clinical trial evaluating Enoxaparin for Fractures, Bone and 6 related conditions. Completed, enrolled 61 participants across 1 site.

Detailed Summary

the risk of bleeding may be greater than the benefit of antithrombotic protection when prophylactically anticoagulating a patient with a lower limb fracture and advanced CKD. The primary objective was to evaluate the risk major bleeding in patients with lower limb fractures and advance CKD. The secondary objectives were to assess major bleeding in patients with lower limb fractures in CKD stage 4 and 5, thrombosis, death.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFractures, Bone, CKD Stage 4, CKD Stage 3, CKD Stage 5, Enoxaparin Adverse Reaction, Anticoagulant-induced Bleeding, Thromboses, Venous
CountriesMexico
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 28, 2025
Enrollment StartMar 1, 2019
Primary CompletionDec 1, 2024
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 1.4 years ago

Interventions

Enoxaparindrug

enoxaparin 1mg/kg of ideal body weight subcutaneous every 24 hours in patients with eGFR \<30ml/min/1.73m2